Cabaletta Bio Appoints Steve Gavel As Chief Commercial Officer To Drive Launch Strategy For Autoimmune Cell Therapies

Cabaletta Bio, Inc., a biotechnology company developing targeted cell therapies for autoimmune diseases, has appointed Steve Gavel as Chief Commercial Officer, effective immediately. In his new role, Gavel will lead the company’s global commercial strategy and execution for rese-cel (resecabtagene autoleucel, formerly CABA-201), Cabaletta’s lead therapeutic candidate. The company expects to submit its first Biologics License Application (BLA) for rese-cel in myositis by 2027, with additional opportunities anticipated across its pipeline.

“Steve is an outstanding leader with a track record of success launching and commercializing cellular therapies. His extensive cell therapy experience will enhance our efforts to maximize the value of rese-cel for patients, payers and providers,” said Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta Bio. “We are confident Steve’s leadership will attract a world-class team to prepare for and to execute the potential launch of rese-cel.”

Before joining Cabaletta, Gavel served as Senior Vice President, Global Cell Therapy Commercial Development at Legend Biotech from 2018 to 2025. There, he built and scaled the global commercial organization, managing CAR T logistics and collaborations with Johnson & Johnson to successfully launch CARVYKTI, a treatment for relapsed or refractory multiple myeloma. His leadership was instrumental in bringing one of the most advanced CAR T cell therapies to market.

“I am honored to join the team at Cabaletta as the Company moves into the next phase of growth with an enhanced focus on commercial planning, development and execution,” said Mr. Gavel. “With a planned first BLA submission for myositis in 2027, I look forward to drawing on my previous experience with successful CAR T launches, building robust commercial foundations and teams that can scale quickly with success and provide enduring value to all stakeholders in my role.”

Earlier in his career, Gavel held key commercial and strategic roles at Celgene (now Bristol Myers Squibb), Takeda Pharmaceuticals, Johnson & Johnson, and Immunex. He earned his B.S. in Finance and Business Administration from Millersville University of Pennsylvania, bringing over two decades of expertise in commercialization, strategic development, and leadership within the biopharma sector to Cabaletta Bio’s mission of delivering curative therapies for autoimmune patients.